ArticleTranslational cancer research2026
Unveiling LAIR1: a prognostic biomarker associated with gastric cancer progression and metastasis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) in immune regulation has been documented, yet its function in gastric cancer (GC) pathogenesis is not well defined. This study sought to evaluate the prognostic relevance and biological influence of LAIR1 in GC development and dissemination. Methods: We employed multi-database bioinformatics to examine LAIR1 expression patterns and their relationship with clinical outcomes. Validation was performed using 177 clinical GC specimens through immunohistochemistry (IHC), western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR). Functional effects of LAIR1 on malignant behaviors were assessed using Results: LAIR1 was markedly upregulated in GC tissues and associated with adverse clinicopathological characteristics, such as poor differentiation, advanced T and N stage, lymph node metastasis, and reduced patient survival. In vitro, LAIR1 depletion attenuated GC cell proliferation, migration, and invasion, whereas its overexpression enhanced these phenotypes. Consistently, LAIR1 knockdown impeded tumor growth and metastasis across all Conclusions: LAIR1 represents a novel prognostic indicator and functional oncoprotein that facilitates GC progression and metastasis, possibly through modulation of the EMT pathway. These findings underscore its potential as a therapeutic target in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.